Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s stock price traded up 1.7% on Friday . The company traded as high as C$3.09 and last traded at C$3.05. 1,431 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 7,410 shares. The stock had previously closed at C$3.00.
Eupraxia Pharmaceuticals Stock Performance
The stock’s 50-day moving average is C$3.19 and its 200 day moving average is C$2.80.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Recommended Stories
- Five stocks we like better than Eupraxia Pharmaceuticals
- What is the Euro STOXX 50 Index?
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What Investors Need to Know to Beat the Market
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Stock Analyst Ratings and Canadian Analyst Ratings
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
